Minimal concentration of human IgM and IgG antibodies necessary to protect mice from challenges with live O6 Escherichia coli
Carregando...
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2011
Editora
WILEY-BLACKWELL
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
MASSIRONI, Silvia Maria Gomes
ARSLANIAN, Christina
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, v.63, n.2, p.193-201, 2011
Resumo
This work evaluated the ability of human anti-lipopolysaccharide O6 IgM and IgG antibodies to protect mice challenged with Escherichia coli serotype O6 : K2ac. Purified IgM-effluent, purified IgG, pools of normal human serum (NHS), or control group were injected into mice 18 h before challenges with O6 E. coli. Interleukin 6 and tumor necrosis factor alpha were quantified in the sera of test and control groups. All mice receiving purified IgM-effluent (66.6 mg L(-1) of antilipopolysaccharide O6 IgM antibodies) and NHS survived. Purified IgG (1.1 mg L(-1) of anti-lipopolysaccharide O6 IgG antibodies) protected 87.5% of the animals. The control group showed no protective ability. The minimal concentration of anti-lipopolysaccharide O6 IgM antibodies, able to protect 50% of the animals was 33.3 mg L(-1) of purified IgM-effluent, whereas purified IgG was able to protect 50% of the animals with only 1.1 mg L(-1) of anti-lipopolysaccharide O6 IgG antibodies. Serum from animals pretreated with purified IgM-effluent and purified IgG before challenges with lipopolysaccharide O6 did not have detectable pro-inflammatory cytokines. Hepatocytes of the control group were completely invaded by bacteria, whereas none was found in animals pretreated with purified IgM-effluent and purified IgG. Higher concentrations of anti-lipopolysaccharide O6 IgM antibodies as compared to anti-lipopolysaccharide O6 IgG antibodies were needed to protect mice from challenges with E. coli O6 serotype.
Palavras-chave
TNF-alpha, IL-6, sepsis, O6 Escherichia coli, anti-lipopolysaccharide antibodies, maternal protection
Referências
- KIM KS, 1988, J INFECT DIS, V157, P47
- Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156
- Naaber P, 2000, J MED MICROBIOL, V49, P431
- ERTEL W, 1995, BLOOD, V85, P1341
- Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269
- Ananias M, 2008, BRAZ J MED BIOL RES, V41, P877, DOI 10.1590/S0100-879X2008001000008
- MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0
- Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271
- Austen WG, 2003, INT J IMMUNOPATH PH, V16, P1
- Barrington R, 2001, IMMUNOL REV, V180, P5, DOI 10.1034/j.1600-065X.2001.1800101.x
- BENNATHAN D, 2003, J INFECT DIS, V288, P5
- DIAS AMG, 1994, REV MICROBIOL, V25, P77
- Hart PH, 1996, IMMUNOLOGY, V89, P599, DOI 10.1046/j.1365-2567.1996.d01-779.x
- Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
- Klein RD, 2000, J SURG RES, V94, P159, DOI 10.1006/jsre.2000.5975
- KOTLOFF KL, 1989, SOUTHERN MED J, V82, P699
- Nasraway SA, 2003, CHEST, V123, p451S, DOI 10.1378/chest.123.5_suppl.451S
- NAVIN TR, 1989, INFECT IMMUN, V57, P1343
- Ng PC, 2004, ARCH DIS CHILD-FETAL, V89, P229
- Pontes GN, 2006, FEMS IMMUNOL MED MIC, V47, P405, DOI 10.1111/j.1574-695X.2006.00107.x
- Pontes GN, 2005, SCAND J IMMUNOL, V62, P353, DOI 10.1111/j.1365-3083.2005.01669.x
- SANTANNA AO, 1989, FEMS MICROBIOL IMMUN, V47, P467
- SIQUEIRA M, 1976, EUR J IMMUNOL, V6, P241, DOI 10.1002/eji.1830060403
- SOUZA CM, 2004, MAMM GENOME, V15, P630, DOI 10.1007/s00335-004-2378-0
- STEIN KE, 1992, J INFECT DIS, V165, pS49
- STUBER F, 1999, TXB ENDOTOXIN HLTH D, P877
- VALDE AA, 1988, J IMMUNOL, V140, P1548
- WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83